TRP_1170x120_3-8-19

Perrigo

Perrigo study looks at “Beating the Holiday Burn”

Perrigo study looks at “Beating the Holiday Burn”

ALLEGAN, Mich. — While the holidays are synonymous with peace, love and joy for many Americans who celebrate, the holiday season is actually filled with physical and emotional discomfort, according to a new survey commissioned by the distributor of store brand Omeprazole Delayed Release Orally Disintegrating Tablets 20 mg (Omeprazole ODT).  The national “Beating the Holiday

Report says Amazon shifting from private label to exclusive brands

Report says Amazon shifting from private label to exclusive brands

SALT LAKE CITY — Private brand expansion has been a major priority for Amazon with several new labels being introduced every year. According to a new report by eCommerce analytics provider One Click Retail, Amazon is now slowing their private brand expansion in favor of introducing a number of Amazon-exclusive brands. Unlike Amazon-owned private labels, these brands

Perrigo readies store-brand Mucinex DM Maximum Strength

Perrigo readies store-brand Mucinex DM Maximum Strength

DUBLIN, Ireland — Perrigo Co. has been cleared by the Food and Drug Administration to market over-the-counter guaifenesin and dextromethorphan hydrobromide extended-release tablets 1200 mg/60 mg, an expectorant and cough suppressant. Perrigo said Wednesday that its guaifenesin and dextromethorphan ER tablets are an OTC generic version of Mucinex DM Maximum Strength tablets from Reckitt Benckiser. Plans call

Amazon tiptoes into OTC market with Basic Care line

Amazon tiptoes into OTC market with Basic Care line

 Amazon.com has made an own-brand foray into the over-the-counter health products market. Published reports said Amazon has quietly introduced a line of OTCs under the Basic Care brand, including items provided by Ireland-based store-brand and generic drug maker Perrigo plc, whose Good Sense private-label products already were sold by the e-tailing giant. The first

Perrigo to release Exalgo generic

Perrigo to release Exalgo generic

DUBLIN, Ireland — Perrigo Co. plc has received approval from the Food and Drug Administration for hydromorphone HCl extended-release tablets 32 mg, an opioid pain medication. Perrigo said it expects to launch its hydromorphone product, a generic verison of Exalgo 32-mg ER tablets from Mallinckrodt, by the end of this month. An opioid agonist, Exalgo

Perrigo to release Mycolog II Cream generic

Perrigo to release Mycolog II Cream generic

DUBLIN, Ireland — Perrigo Co. plc has received approval from the Food and Drug Administration for nystatin and triamcinolone acetonide cream 100,000 units/gram and 1 mg/gram, an antifungal medication. The company said Wednesday that its nystatin and triamcinolone acetonide product is a generic version of Mycolog II Cream from Bristol-Myers Squibb. The branded product was

Perrigo releases store-brand Women’s Rogaine

Perrigo releases store-brand Women’s Rogaine

DUBLIN, Ireland — Perrigo Co. plc has begun shipping a store-brand version of Women’s Rogaine, a foam hair regrowth treatment. Perrigo said it’s the first to market with an over-the-counter, private-label version of minoxidil topical aerosol foam 5%. The product is packaged and marketed as a store brand or retailer “own label brand and provides

Perrigo cleared to market cough syrup

Perrigo cleared to market cough syrup

DUBLIN, Ireland — Perrigo Co. plc has received approval from the Food and Drug Administration for hydrocodone bitartrate and homatropine methylbromide oral solution 5 mg/1.5 mg per 5 ml. Hydrocodone bitartrate and homatropine methylbromide syrup is indicated for the symptomatic relief of cough in adults and children ages 6 and older. A combination medication, the

Perrigo licenses meth-resistant tech for PSE products

Perrigo licenses meth-resistant tech for PSE products

DUBLIN, Ireland — Perrigo Co. plc is bringing in methamphetamine-blocking capability for pseudoephedrine (PSE) products. On Tuesday, Perrigo said it has entered an exclusive licensing agreement with St. Louis-based Highland Pharmaceuticals for its Tarex meth-blocking technology. The deal also includes the distribution rights of Zephrex-D, the pseudoephedrine nasal decongestant marketed by Highland’s Westport Pharmaceuticals unit.

Perrigo to buy OTC distributor Geiss, Destin & Dunn

Perrigo to buy OTC distributor Geiss, Destin & Dunn

DUBLIN, Ireland — Perrigo Co. plc plans to acquire Geiss, Destin & Dunn Inc., a U.S. distributor of over-the-counter health care, personal care and consumer products. Financial terms of the deal weren’t disclosed. Perrigo said Wednesday that it expects to finalize the Geiss, Destin & Dunn (GDD) transaction by the end of August. Based in

Perrigo finalizes sale of vitamins business to IVC

Perrigo finalizes sale of vitamins business to IVC

DUBLIN, Ireland — Perrigo Co. plc has wrapped up the sale of its U.S. vitamins, minerals and supplements (VMS) business to International Vitamin Corp. (IVC). The cash deal, terms of which weren’t disclosed, was announced in late June. The VMS business was part of the Perrigo Nutritionals division, whose core products are store-brand infant formula

Perrigo releases store-brand version of Zegerid OTC

Perrigo releases store-brand version of Zegerid OTC

DUBLIN, Ireland — Perrigo Co. plc has received approval from the Food and Drug Administration for omeprazole and sodium bicarbonate capsules 20 mg/1100 mg, an over-the-counter medicine for heartburn. Perrigo said Monday that its product marks the first store-brand launch of an equivalent to Bayer’s Zegerid OTC capsules. Shipments to retail customers are under way,

Perrigo to sell VMS business to IVC

Perrigo to sell VMS business to IVC

DUBLIN, Ireland — Perrigo Co. plc plans to sell its U.S. vitamins, minerals and supplements (VMS) business to International Vitamin Corp. (IVC). Financial terms of the deal weren’t disclosed. Perrigo said Monday that the company had been looking to sell off its VMS business and that it expects the transaction to close by early August,

1 2 3